Rapha Capital Management plays a leading role in managing a number of other investment vehicles, including:
Rapha Capital Management, LLC is an investment management firm located in Miami, Florida, focusing on strategic investments tin early stage, non-public biotechnology companies. Rapha Capital was founded by its President, Kevin Slawin, MD, a successful and experienced oncologic and robotic surgeon, biotech consultant, investor, and founder focusing on technologies in oncology, T cells and immunotherapy, as well as other breakthrough healthcare technologies. Rapha Capital Management manages thirteen legacy SPIVs, Rapha Capital Investment I – XIII, with investments in a wide range of early stage biotech companies.
LEARN MORE
According to RCM’s Founder and Managing Partner, Kevin Slawin, M.D., successfully identifying future successful biotech investment targets at, or just prior to, the Series A stage requires a wide range of knowledge, experience, and a little bit of luck. He believes there is no “formula” that can be applied by investment “technicians” to reliably identify future successful companies. Dr. Slawin has a unique mix of experience as a robotic oncologic surgeon, academician, basic and clinical researcher, biotech founder and investor, as well as public biotech operator. His expertise is focused in disruptive technologies in oncology, T cells and immunotherapy, as well as other breakthrough healthcare technologies. Dr. Slawin is also the founder of Bellicum Pharmaceuticals, Inc., which he successfully took public in an approximately $161 million initial public offering (“IPO”) in December 2014. He also plays a guiding role in several of the investments managed by RCM in certain companies, for instance, serving as a board member at 3DBio Therapeutics, Inc., FIZE Medical, Inc., K-2 Biolabs Acclerator, LLC and Demeetra AgBio, Inc. He served as a board member and interim CEO of portfolio company AsclepiX Therapeutics, Inc., engineering their $35 million Series A financing led by Perceptive Xontogeny Venture Fund in 2020. He is the founder and CEO of PONCE Therapeutics, Inc., a company leveraging the growing scientific knowledge surrounding the aging process to develop anti-aging technologies, reuniting the team that founded Bellicum Pharmaceuticals to focus on the anti-aging space, which he believes will soon rival oncology in both interest and value.
He is the founder and managing partner of Miami Medicos, LLC, a growing group of physicians, founders, executives and investors working to expand the entrepreneurial healthcare ecosystem in Miami and South Florida.
He is co-Inventor of the FDA-approved “prostate health index (PHI)” test licensed and marketed by Beckman Coulter and utilized around the world. He has published in medical and scientific journals including the Journal of the American Medical Association (JAMA), Journal of the National Cancer Institute (JNCI), and the New England Journal of Medicine (NEJM). In addition to his publications, Dr. Slawin has also been listed in America’s Top Doctors for Cancer (Castle Connolly Medical). RCM manages Rapha Capital Investment I through XIII, which are thirteen legacy special purpose investment vehicles (“SPIVs”) that currently manage early-stage biotech investments since it was formed in2017. RCM also manages Rapha Capital BioVentures Fund I, LP (the “RCBV Fund”) that is also solely focused on investment in early-stage life science companies, and that builds on the experience, success and investor base from Rapha Capital I – XIII.
Rapha Capital BioVentures Fund I, LP (“RCBVFI”), is a venture capital fund managed by Kevin Slawin, MD, the Founder and Managing Partner of Rapha Capital Management, LLC (“RCM”), along with an experienced team of advisors and financial managers assembled by RCM. RCBVFI is focused on securing the investment lead, typically at Series A or just before, in target companies that RCM believes have developed transformative products, technologies, or processes that will drive long-term value creation for investors.
